WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H596528
CAS#: 111035-59-7
Description: L 365031 is a CCK antagonist.
Hodoodo Cat#: H596528
Name: L 365031
CAS#: 111035-59-7
Chemical Formula: C23H18BrN3O2
Exact Mass: 447.06
Molecular Weight: 448.320
Elemental Analysis: C, 61.62; H, 4.05; Br, 17.82; N, 9.37; O, 7.14
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @hodoodo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: L 365031; L-365031; L365031; L 365,031; L-365,031; L365,031;
IUPAC/Chemical Name: 4-bromo-N-(1-methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-yl)benzamide
InChi Key: FHCLUARBHKHIQK-UHFFFAOYSA-N
InChi Code: InChI=1S/C23H18BrN3O2/c1-27-19-10-6-5-9-18(19)20(15-7-3-2-4-8-15)25-21(23(27)29)26-22(28)16-11-13-17(24)14-12-16/h2-14,21H,1H3,(H,26,28)
SMILES Code: O=C(NC1C(N(C)C2=CC=CC=C2C(C3=CC=CC=C3)=N1)=O)C4=CC=C(Br)C=C4
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 448.32 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Hendrie CA, Neill JC, Shepherd JK, Dourish CT. The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiol Behav. 1993 Oct;54(4):689-93. PubMed PMID: 7902586.
2: Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD. The selective CCK-B receptor antagonist L-365,260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol. 1990 Jan 25;176(1):35-44. PubMed PMID: 2311658.
3: Chang RS, Chen TB, Bock MG, Freidinger RM, Chen R, Rosegay A, Lotti VJ. Characterization of the binding of [3H]L-365,260: a new potent and selective brain cholecystokinin (CCK-B) and gastrin receptor antagonist radioligand. Mol Pharmacol. 1989 Jun;35(6):803-8. PubMed PMID: 2733696.
4: Hill DR, Campbell NJ, Shaw TM, Woodruff GN. Autoradiographic localization and biochemical characterization of peripheral type CCK receptors in rat CNS using highly selective nonpeptide CCK antagonists. J Neurosci. 1987 Sep;7(9):2967-76. PubMed PMID: 3625281.
5: Hill DR, Shaw TM, Woodruff GN. Species differences in the localization of 'peripheral' type cholecystokinin receptors in rodent brain. Neurosci Lett. 1987 Aug 31;79(3):286-9. PubMed PMID: 3658220.
